Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding
Others
Ratios

Applied Therapeutics (APLT) Operating Expenses (2023 - 2025)

Historic Operating Expenses for Applied Therapeutics (APLT) over the last 3 years, with Q3 2025 value amounting to $17.8 million.

  • Applied Therapeutics' Operating Expenses fell 4053.91% to $17.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $99.4 million, marking a year-over-year increase of 4022.15%. This contributed to the annual value of $104.8 million for FY2024, which is 4055.66% up from last year.
  • As of Q3 2025, Applied Therapeutics' Operating Expenses stood at $17.8 million, which was down 4053.91% from $23.1 million recorded in Q2 2025.
  • Applied Therapeutics' 5-year Operating Expenses high stood at $33.0 million for Q4 2024, and its period low was $100000.0 during Q1 2024.
  • Moreover, its 3-year median value for Operating Expenses was $20.6 million (2024), whereas its average is $20.4 million.
  • Its Operating Expenses has fluctuated over the past 5 years, first plummeted by 9953.53% in 2024, then soared by 2542500.0% in 2025.
  • Quarter analysis of 3 years shows Applied Therapeutics' Operating Expenses stood at $20.3 million in 2023, then soared by 62.34% to $33.0 million in 2024, then crashed by 46.22% to $17.8 million in 2025.
  • Its last three reported values are $17.8 million in Q3 2025, $23.1 million for Q2 2025, and $25.5 million during Q1 2025.